Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Current Deferred Revenue (2016 - 2018)

Altimmune (ALT) has disclosed Current Deferred Revenue for 7 consecutive years, with $19753.0 as the latest value for Q3 2018.

  • On a quarterly basis, Current Deferred Revenue rose 6.05% to $19753.0 in Q3 2018 year-over-year; TTM through Sep 2018 was $19753.0, a 6.05% increase, with the full-year FY2017 number at $15914.0, up 10.61% from a year prior.
  • Current Deferred Revenue was $19753.0 for Q3 2018 at Altimmune, down from $172414.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $172414.0 in Q2 2018 to a low of $14388.0 in Q4 2016.
  • A 4-year average of $47545.2 and a median of $26003.0 in 2017 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: tumbled 92.88% in 2014, then skyrocketed 434.57% in 2018.
  • Altimmune's Current Deferred Revenue stood at $62261.0 in 2014, then tumbled by 76.89% to $14388.0 in 2016, then increased by 10.61% to $15914.0 in 2017, then grew by 24.12% to $19753.0 in 2018.
  • Per Business Quant, the three most recent readings for ALT's Current Deferred Revenue are $19753.0 (Q3 2018), $172414.0 (Q2 2018), and $44753.0 (Q1 2018).